No abstract

Location awareness is an important capability for mobile computing. Yet inexpensive, pervasive positioning-a requirement for wide-scale adoption of location-aware computing-has been elusive. We demonstrate a radio beacon-based approach to location, called Place Lab, that can overcome the lack of ubiquity and high-cost found in existing location sensing approaches. Using Place Lab, commodity laptops, PDAs and cell phones estimate their position by listening for the cell IDs of fixed radio beacons, such as wireless access points, and referencing the beacons' positions in a cached database. We present experimental results showing that 802.11 and GSM beacons are sufficiently pervasive in the greater Seattle area to achieve 20-40 meter median accuracy with nearly 100% coverage measured by availability in people's daily lives.

Absolute rate constants have been measured for the autoxidation of a large number of hydrocarbons a t 30 OC. The chain-propagating and chain-terminating rate constants depend on the structure of the hydrocarbon and also on the structure of the chain-carrying peroxy radical. With certain notable exceptions which are mainly due to steric hindrance, the rate constants for hydrogen-atom abstraction increase in the order primary < secondary < tertiary; and, for compounds losing a secondary hydrogen atom, the rate constants increase in the order unactivated < acyclic activated by a single T-electron system < cyclic activated by a single T-system < acyclic activated by two T-systems < cyclic activated by two Tsystems. The rate constants for chain termination by the self-reaction of two peroxy radicals generally increase in the order tertiary peroxy radicals < acyclic allylic secondary ,< cyclic secondary < acyclic benzylic secondary < primary peroxy radicals < hydroperoxy radicals.

Die gegenüber den entsprechenden Kohlenwasserstoffen und strukturgleichen Ethem reaktionsfreudigeren Amine wie z.B. Triethylamin, Triethylendiamin, Pyrrolidin und tert‐Butylamin liefern Geschwindigkeitskonstanten zwischen 3.3 ‐ 10°C ‐4.4‐ 109 /M‐s für die Titelreaktionen.

ObjectiveTo evaluate the safety and efficacy of efgartigimod in patients with generalized myasthenia gravis (MG) enrolled in the ADAPT+ long-term extension study.BackgroundTreatment with efgartigimod, a human IgG1 antibody Fc-fragment that blocks neonatal Fc receptor, resulted in clinically meaningful improvement (CMI) in MG-specific outcome measures in the ADAPT phase 3 clinical trial. All patients who completed ADAPT were eligible to enroll in its ongoing open-label, 3-year extension study, ADAPT+.Design/MethodsEfgartigimod (10 mg/kg IV) was administered in cycles of once-weekly infusions for 4 weeks, with subsequent cycles initiated based on clinical evaluation. Efficacy was assessed during each cycle utilizing Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scales.ResultsNinety-one percent of ADAPT patients (151/167) entered ADAPT+. As of February 2021, 106 AChR-Ab+ and 33 AChR-Ab– patients had received at least 1 dose of open-label efgartigimod (including 66 ADAPT placebo [PBO] patients). The mean (SD) study duration was 363 (114) days, resulting in 138 patient-years of observation. Similar incidence rates per patient year (IR/PY) of serious adverse events were seen in ADAPT (efgartigimod: 0.11; placebo: 0.29) compared to ADAPT+ (0.25). Five deaths (acute myocardial infarction, COVID-19 pneumonia/septic shock, bacterial pneumonia/MG crisis, malignant lung neoplasm, and unknown [multiple cardiovascular risk factors identified on autopsy]) occurred; none were considered related to efgartigimod by the investigator. AEs were predominantly mild or moderate. CMI was observed in AChR-Ab+ patients during each cycle (up to 10 cycles) at magnitudes comparable to improvements observed at week 3 of cycle 1 (mean[SE] improvements: MG-ADL, –5.1[0.34]; QMG, –4.7[0.41]). Clinical improvements mirrored maximal reductions in total IgG and AChR-Abs across all cycles.ConclusionsThis analysis suggests the efficacy of long-term treatment with efgartigimod was consistent across multiple cycles. No new safety signals were identified, despite being conducted before vaccine availability during the COVID-19 pandemic.